Skip to content

The Protocol of A multi-center, randomized, parallel-group, controlled trial of retropetoneal laparoscopic radical nephrectomy and transperitoneal laparoscopic radical nephrectomy in the treatment of renal cell carcinoma

The Protocol of A multi-center, randomized, parallel-group, controlled trial of retropetoneal laparoscopic radical nephrectomy and transperitoneal laparoscopic radical nephrectomy in the treatment of renal cell carcinoma

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071130
Enrollment
Unknown
Registered
2023-05-05
Start date
2023-05-10
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Experimental group:Laparoscopic radical nephrectomy was performed by transperitoneal approach
The control group:Laparoscopic radical nephrectomy was performed through retroperitoneal space

Sponsors

The second hospital of lanzhou university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients and his families who volunteered to participate this study. And Patient is informed and has given written informed consent. 2.18 years of age and less than 75 years of age, both men and women; 3. Preoperative diagnosis is Limited renal cancer (stage T1 ~ T3aN0M0), but should be excluded except for small renal cell carcinoma; 4. No previous history of other malignant tumors.

Exclusion criteria

Exclusion criteria: 1. tumor has invaded the inferior vena cava or renal pedicle lymph node metastasis; 2. lack of behavioral ability or limited behavioral ability; 3. Routine preoperative chest X-ray and abdominopelvic enhanced CT examination found distant metastasis without radical surgical conditions or intraoperative exploration found extensive local invasion of advanced tumors; 4. surgery combined with other organ resection or laparoscopic surgery converted to laparotomy; 5. patients with other serious diseases, including cardiovascular, respiratory, renal, or liver diseases, combined with poorly controlled hypertension, diabetes; 6. pregnant and lactating women; 7. History of abdominal surgery or retroperitoneal surgery or ipsilateral surgery; 8. history of preoperative chemotherapy; 9. severe coagulation dysfunction electrolyte balance disorder hypoproteinemia after active correction without significant improvement; 10. allergic to anesthetic drugs, poor cardiopulmonary function and other anesthesia contraindications; 11. any other condition that the investigator considers inappropriate for participation in the trial;

Design outcomes

Primary

MeasureTime frame
Recurrence free survival ;

Secondary

MeasureTime frame
overall survival;The operation time;The amount of blood lost during the operation;Postoperative hospital stay;Cost from post-operation to discharge;Perioperative complications;

Countries

China

Contacts

Public Contactpanfeng Shang

The second hospital of lanzhou university

shangpf@lzu.edu.cn+86 13919785295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026